Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17991430rdf:typepubmed:Citationlld:pubmed
pubmed-article:17991430lifeskim:mentionsumls-concept:C0206131lld:lifeskim
pubmed-article:17991430lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:17991430lifeskim:mentionsumls-concept:C1739661lld:lifeskim
pubmed-article:17991430pubmed:issue1-2lld:pubmed
pubmed-article:17991430pubmed:dateCreated2007-12-24lld:pubmed
pubmed-article:17991430pubmed:abstractTextPreviously, bis(alpha-furancarboxylato)oxovanadium(IV)(BFOV) exhibited potent hypoglycemic activity in diabetic animals. We evaluated the effects of BFOV on lipolysis in isolated rat adipocytes and lipid metabolism in fat-fed/streptozotocin (STZ)-induced diabetic rats, an animal model of type 2 diabetes.lld:pubmed
pubmed-article:17991430pubmed:languageenglld:pubmed
pubmed-article:17991430pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17991430pubmed:citationSubsetIMlld:pubmed
pubmed-article:17991430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17991430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17991430pubmed:statusMEDLINElld:pubmed
pubmed-article:17991430pubmed:monthFeblld:pubmed
pubmed-article:17991430pubmed:issn0009-8981lld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:LiN JNJlld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:NgomN NNNlld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:LiuWeipingWlld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:GaoLihuiLlld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:ChenZhiheZlld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:XieMingjinMlld:pubmed
pubmed-article:17991430pubmed:authorpubmed-author:NiuYanfenYlld:pubmed
pubmed-article:17991430pubmed:issnTypePrintlld:pubmed
pubmed-article:17991430pubmed:volume388lld:pubmed
pubmed-article:17991430pubmed:ownerNLMlld:pubmed
pubmed-article:17991430pubmed:authorsCompleteYlld:pubmed
pubmed-article:17991430pubmed:pagination89-94lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:meshHeadingpubmed-meshheading:17991430...lld:pubmed
pubmed-article:17991430pubmed:year2008lld:pubmed
pubmed-article:17991430pubmed:articleTitleThe antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.lld:pubmed
pubmed-article:17991430pubmed:affiliationYunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, Kunming, PR China.lld:pubmed
pubmed-article:17991430pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17991430pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed